GlassScriptPhysician profile
Michael T Beckham
NPI 1053303248
$8,828.67
in general payments reported to CMS, 2019-2025
43 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $1,429 · 2021: $1,632 · 2022: $1,667 · 2023: $1,618 · 2024: $604 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,630 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,630.10 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,658.89 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,271.27 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $860.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $840.68 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Lilly USA, LLC | $531.31 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $504.90 | 2019-2025 | |
| Abbvie INC. | $412.36 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Astellas Pharma US INC | $378.22 | 2019-2023 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.03 | 2019-2025 | Jardiance, Synjardy |
| Currax Pharmaceuticals LLC | $206.90 | 2019-2023 | Contrave, Onzetra Xsail |
| Esperion Therapeutics, INC. | $205.20 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $173.67 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.61 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $117.46 | 2019-2022 | |
| Shield Therapeutics INC | $116.71 | 2022-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Beckham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.